Resources

The success of pulse oximetry scale-up depends in part on a growing demand for pulse oximeters by health experts, civil society, and government stakeholders. This messaging map is designed primarily for advocates who are delivering messages about the importance of pulse oximeters to health decision-makers, policymakers, and political stakeholders.This resource is part of the Pulse Oximetry Primer.

Next-generation sequencing (NGS) is a powerful, high-throughput technology that enables rapid and comprehensive analysis of genetic material, offering unparalleled sensitivity for detecting known and unknown contaminants, verifying product integrity, and supporting regulatory compliance.This webinar discusses the practical applicability of NGS sequencing for vaccine development and testing by low- and middle-income country manufacturers (LMICs). This two-day webinar provides up-to-date information and guidance from subject matter experts on NGS methodology, validation, regulatory expectations, and controls. It features two real-world case studies and a panel discussion between regulatory experts.Speakers include:Kutub Mahmood, PhD, Project Director, Polio Vaccines, Center for Vaccine Innovation and Access, PATHTara Tagmyer, PhD, Scientific Director, Bacterial & Parasitic Diseases, Center for Vaccine Innovation and Access, PATHColette Cote, PhD, US General Manager and Chief Scientific and Portfolio Officer, PathoQuestArifa Khan, PhD, Head, Molecular Retrovirology Unit, Division of Viral Products, Office of Vaccines Research and Review in the Center for Biologics Evaluation and Research, US Food and Drug AdministrationBradley Hasson, MBA, Director of Lab Operations for Next Generation Sequencing, Millipore SigmaLeyla Diaz, PhD, Technical Consultant, Scientific and Regulatory Consultancy, Millipore SigmaKonstantin Chumakov, PhD, Adjunct Professor, George Washington University and University of MarylandJavier Martin, PhD, Principal Scientist, Medicines and Healthcare products Regulatory Agency (UK)Manasi Majumdar, PhD, Principal Scientist, Medicines and Healthcare products Regulatory Agency (UK)Yola Eka Erwinda, MS, Senior Laboratory Officer, Biological Products Laboratory Division, Indonesian Food and Drug ControlDevendra Barthwal, MS, Assistant Technical Officer, Central Drugs Laboratory, Kasauli, India, and certified WHO InspectorPlease note: The slides and recording from Day 2 presentation 2.3 are temporarily unavailable. They will be added to this site at a future date.

This report shares the results of a value proposition study that PATH conducted to better understand stakeholder perspectives in four countries on potential use cases and target populations for a human hookworm vaccine and to explore the idea of a hookworm/malaria combination vaccine. The Democratic Republic of Congo, Ghana, Malawi, and Uganda were selected for the study because they all have demonstrated hookworm and malaria disease burdens. Providing protection against both diseases with a single vaccine could offer an efficient, effective, and affordable way to improve health in low- and middle-income countries.

For nearly 50 years, PATH has advanced women's and girls' health by designing solutions that meet women where they are—at home, in their communities, and through technologies that prioritize choice, control, and dignity.Across Latin America and the Caribbean, PATH partners with ministries of health, civil society, and communities to make care more accessible, equitable, and centered on women's needs—shifting toward solutions that bring essential services directly to women.This fact sheet provides an overview of PATH's women's health work in Latin America and the Caribbean.

A summary of our impact, achievements, and finances.